行情

CDTX

CDTX

Cidara
NASDAQ

实时行情|Nasdaq Last Sale

2.650
-0.040
-1.49%
已收盘, 16:00 12/11 EST
开盘
2.690
昨收
2.690
最高
2.750
最低
2.600
成交量
16.29万
成交额
--
52周最高
3.300
52周最低
1.223
市值
8,755.68万
市盈率(TTM)
-1.9095
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CDTX 新闻

  • Benzinga's Top Upgrades, Downgrades For December 4, 2019
  • Benzinga.12/04 15:16
  • Raymond James likes Zimmer Biomet in premarket analyst action
  • Seeking Alpha - Article.12/04 13:46
  • WBB Securities Upgrades Cidara Therapeutics to Buy, Announces $6.25 Price Target
  • Benzinga.12/04 13:32
  • Cidara Therapeutics to Present at Two Upcoming Medical Conferences
  • GlobeNewswire.12/03 13:00

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CDTX 简况

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
展开

Webull提供Cidara Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。